[go: up one dir, main page]

MX2014007125A - Uso de n-hidroxisuccinimida para mejorar la estabilidad de conjugados. - Google Patents

Uso de n-hidroxisuccinimida para mejorar la estabilidad de conjugados.

Info

Publication number
MX2014007125A
MX2014007125A MX2014007125A MX2014007125A MX2014007125A MX 2014007125 A MX2014007125 A MX 2014007125A MX 2014007125 A MX2014007125 A MX 2014007125A MX 2014007125 A MX2014007125 A MX 2014007125A MX 2014007125 A MX2014007125 A MX 2014007125A
Authority
MX
Mexico
Prior art keywords
hydroxysuccinimide
nhs
conjugate stability
improve conjugate
improve
Prior art date
Application number
MX2014007125A
Other languages
English (en)
Inventor
Fang Liu
Godfrey W Amphlett
Deborah H Meshulam
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of MX2014007125A publication Critical patent/MX2014007125A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invención proporciona procesos para elaborar conjugados de agente de unión celulares y agente citotóxico con estabilidad mejorada en presencia de NHS exógena. En algunas modalidades, el proceso inventivo comprende la adición de una relación molar de NHS exógena a la cantidad de NHS generada durante la reacción de modificación como resultado de la hidrólisis/aminólisis del enlazador bifuncional.
MX2014007125A 2011-12-13 2012-12-13 Uso de n-hidroxisuccinimida para mejorar la estabilidad de conjugados. MX2014007125A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161570139P 2011-12-13 2011-12-13
PCT/US2012/069527 WO2013090590A1 (en) 2011-12-13 2012-12-13 Use of n-hydroxysuccinimide to improve conjugate stability

Publications (1)

Publication Number Publication Date
MX2014007125A true MX2014007125A (es) 2015-04-16

Family

ID=48613179

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014007125A MX2014007125A (es) 2011-12-13 2012-12-13 Uso de n-hidroxisuccinimida para mejorar la estabilidad de conjugados.

Country Status (14)

Country Link
US (1) US20140350228A1 (es)
EP (1) EP2790724A4 (es)
JP (1) JP2015504869A (es)
KR (1) KR20140107418A (es)
CN (1) CN104093425A (es)
AU (1) AU2012352210A1 (es)
BR (1) BR112014014464A8 (es)
CA (1) CA2859444A1 (es)
EA (1) EA201491173A1 (es)
HK (1) HK1203364A1 (es)
IL (1) IL233086A0 (es)
MX (1) MX2014007125A (es)
SG (2) SG11201403179QA (es)
WO (1) WO2013090590A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL282138B2 (en) 2005-08-24 2024-01-01 Immunogen Inc Process for preparing purified drug conjugates
RS58810B1 (sr) 2009-06-03 2019-07-31 Immunogen Inc Metodi konjugacije
SMT201900114T1 (it) 2011-03-29 2019-02-28 Immunogen Inc Preparazione di coniugati maytansinoide-anticorpo mediante un processo a fase unica
NZ707091A (en) 2012-10-04 2018-12-21 Immunogen Inc Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
CA2914189C (en) * 2013-06-21 2023-03-14 Innate Pharma Enzymatic conjugation of polypeptides
CN106267225B (zh) * 2015-05-29 2020-03-06 上海新理念生物医药科技有限公司 三马来酰亚胺型连接子及其应用
WO2017178828A1 (en) 2016-04-14 2017-10-19 Polytherics Limited Conjugates and conjugating reagents comprising a linker that includes at least two (-ch2-ch2-0-) units in a ring
GB201615725D0 (en) 2016-09-15 2016-11-02 Polytherics Ltd Novel cytotoxic agents and conjugates thereof
CN113336823A (zh) * 2021-05-28 2021-09-03 联宁（苏州）生物制药有限公司 一种用于抗体偶联药物连接子lnd1067的合成方法
WO2025151380A1 (en) * 2024-01-08 2025-07-17 Azvlz, Inc. Functionalized conjugation crosslinkers and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2835829B1 (fr) * 2002-02-13 2007-09-14 Centre Nat Rech Scient Nouveau procede de preparation de biopuces a adn ou a proteines et leurs applications
DE10242076A1 (de) * 2002-09-11 2004-03-25 Fresenius Kabi Deutschland Gmbh HAS-Allergen-Konjugate
IL282138B2 (en) * 2005-08-24 2024-01-01 Immunogen Inc Process for preparing purified drug conjugates
EP1959958A4 (en) * 2005-11-14 2010-07-14 Univ Southern California INTEGRIN-BINDING SMALL MOLECULES
SI2019104T1 (sl) * 2007-07-19 2013-12-31 Sanofi Citotoksična sredstva, ki obsegajo nove tomaimicinske derivate, in njihova terapevtska uporaba
EP3100745B1 (en) * 2009-02-05 2018-04-18 Immunogen, Inc. Novel benzodiazepine derivatives
RS58810B1 (sr) * 2009-06-03 2019-07-31 Immunogen Inc Metodi konjugacije

Also Published As

Publication number Publication date
IL233086A0 (en) 2014-07-31
EP2790724A4 (en) 2015-08-05
WO2013090590A1 (en) 2013-06-20
KR20140107418A (ko) 2014-09-04
EA201491173A1 (ru) 2014-11-28
SG11201403179QA (en) 2014-07-30
JP2015504869A (ja) 2015-02-16
HK1203364A1 (en) 2015-10-30
CN104093425A (zh) 2014-10-08
SG10201604747WA (en) 2016-08-30
CA2859444A1 (en) 2013-06-20
EP2790724A1 (en) 2014-10-22
AU2012352210A1 (en) 2014-07-24
BR112014014464A2 (pt) 2017-06-13
US20140350228A1 (en) 2014-11-27
BR112014014464A8 (pt) 2017-06-13

Similar Documents

Publication Publication Date Title
MX2014007125A (es) Uso de n-hidroxisuccinimida para mejorar la estabilidad de conjugados.
MX339927B (es) Preparacion de conjugados de maitansinoides y anticuerpos mediante un proceso de una etapa.
NZ741211A (en) Self-stabilizing linker conjugates
MY171008A (en) Preparation of maytansinoid antibody conjugates by a one-step process
MX343337B (es) Metodos de preparacion de conjugados.
EP4253395A3 (en) Processes for the preparation of carbohydrate conjugated rna agents
SG195172A1 (en) Novel maytansinoid derivatives with peptide linker and conjugates thereof
MX2024002632A (es) Enlazadores que contienen peptido para conjugados anticuerpo-farmaco.
NZ588884A (en) Cross-linkers and their uses
MX2012000575A (es) Conjugados de epsilon-polilisina y uso de los mismos.
PH12014502826A1 (en) Immunoconjugates comprising anti-cd79b antibodies
MY170719A (en) Antibody-drug conjugates
SG195196A1 (en) Dual targeting
MX2015002482A (es) Composicion inmunogenica.
MX2015008027A (es) Proceso de glicoconjugacion.
PH12015500667A1 (en) Antibody-drug conjugate
MX2013003452A (es) Conjugados de amatoxina con enlazantes mejorados.
PH12014501229A1 (en) Antibody-drug conjugates and related compounds, compositions, and methods
MX2013011201A (es) Proceso para la elaboracion de conjugados de mejor homogeneidad.
GB201103836D0 (en) Conjugation process
NZ703581A (en) Anti-cd70 antibody drug conjugates
WO2013067199A3 (en) Subcutaneous delivery of polymer conjugates of therapeutic agents
WO2013103301A3 (en) Method for preparing cell targeting conjugates, and the complexes obtained
PH12016501602A1 (en) Method for activation and conjugation of biomolecules
MX2012014796A (es) Proceso para preparar 4-hidroxipiridinas.